CR20190273A - Anticuerpos y polipéptidos dirigidos contra cd127 - Google Patents
Anticuerpos y polipéptidos dirigidos contra cd127Info
- Publication number
- CR20190273A CR20190273A CR20190273A CR20190273A CR20190273A CR 20190273 A CR20190273 A CR 20190273A CR 20190273 A CR20190273 A CR 20190273A CR 20190273 A CR20190273 A CR 20190273A CR 20190273 A CR20190273 A CR 20190273A
- Authority
- CR
- Costa Rica
- Prior art keywords
- antibodies
- directed against
- therapeutic
- applications
- polypeptides directed
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
Abstract
La invención se encuentra el campo de los anticuerpos útiles en aplicaciones terapéuticas y de diagnóstico con diana en CD127, la cadena alfa del receptor de IL7, y provee en particular, anticuerpos monoclonales humanizados contra CD127, particularmente CD127 humano, sus usos terapéuticos y aplicaciones de tipo diagnóstico.The invention is in the field of antibodies useful in therapeutic and diagnostics applications targeting CD127, the alpha chain of the IL7 receptor, and provides in particular humanized monoclonal antibodies against CD127, particularly human CD127, therapeutic uses thereof, and diagnostics applications.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16306655 | 2016-12-09 | ||
| PCT/EP2017/081911 WO2018104483A1 (en) | 2016-12-09 | 2017-12-07 | Antibodies and polypeptides directed against cd127 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20190273A true CR20190273A (es) | 2019-10-17 |
Family
ID=57796143
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20190273A CR20190273A (es) | 2016-12-09 | 2017-12-07 | Anticuerpos y polipéptidos dirigidos contra cd127 |
Country Status (39)
| Country | Link |
|---|---|
| US (3) | US11098128B2 (es) |
| EP (1) | EP3551664B1 (es) |
| JP (1) | JP6986559B2 (es) |
| KR (1) | KR102306366B1 (es) |
| CN (1) | CN110392695B (es) |
| AR (1) | AR110326A1 (es) |
| AU (1) | AU2017373819B2 (es) |
| BR (1) | BR112019010595A2 (es) |
| CA (1) | CA3042582C (es) |
| CL (1) | CL2019001530A1 (es) |
| CO (1) | CO2019005909A2 (es) |
| CR (1) | CR20190273A (es) |
| CY (1) | CY1124153T1 (es) |
| DK (1) | DK3551664T3 (es) |
| EA (1) | EA201991005A1 (es) |
| ES (1) | ES2867900T3 (es) |
| HR (1) | HRP20210697T1 (es) |
| HU (1) | HUE054206T2 (es) |
| IL (1) | IL266837B (es) |
| LT (1) | LT3551664T (es) |
| MA (1) | MA49727B1 (es) |
| MD (1) | MD3551664T2 (es) |
| MX (1) | MX2019006577A (es) |
| MY (1) | MY190770A (es) |
| NZ (1) | NZ753213A (es) |
| PE (1) | PE20191152A1 (es) |
| PH (1) | PH12019501285B1 (es) |
| PL (1) | PL3551664T3 (es) |
| PT (1) | PT3551664T (es) |
| RS (1) | RS61808B1 (es) |
| RU (1) | RU2769352C2 (es) |
| SA (1) | SA519401906B1 (es) |
| SI (1) | SI3551664T1 (es) |
| SM (1) | SMT202100267T1 (es) |
| TW (1) | TWI777996B (es) |
| UA (1) | UA126386C2 (es) |
| UY (1) | UY37511A (es) |
| WO (1) | WO2018104483A1 (es) |
| ZA (1) | ZA201902743B (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107427577A (zh) | 2015-03-31 | 2017-12-01 | 韦斯夸尔德有限公司 | 具有蛋白酶可切割接头的肽构建体 |
| WO2016156468A1 (en) | 2015-03-31 | 2016-10-06 | Vhsquared Limited | Polypeptides |
| WO2017125578A1 (en) | 2016-01-21 | 2017-07-27 | Vhsquared Limited | Polypeptides |
| US12016900B2 (en) | 2017-06-04 | 2024-06-25 | Rappaport Family Institute For Research In The Medical Sciences | Method of treating cancer with an immune checkpoint inhibitor in combination with another therapeutic agent |
| CA3066054A1 (en) * | 2017-06-04 | 2018-12-13 | Rappaport Family Institute For Research In The Medical Sciences | Method of predicting personalized response to cancer therapy and kit therefor |
| US12070489B2 (en) | 2018-12-12 | 2024-08-27 | Rappaport Family Institute For Research In The Medical Sciences | Method of treating cancer with a cancer therapy in combination with another therapeutic agent |
| CN113396162B (zh) | 2019-01-22 | 2024-08-16 | 百时美施贵宝公司 | 抗IL-7Rα亚基的抗体及其用途 |
| AU2020296979A1 (en) | 2019-06-21 | 2022-02-24 | Sorriso Pharmaceuticals, Inc. | Polypeptides |
| US12247079B2 (en) | 2019-06-21 | 2025-03-11 | Sorriso Pharmaceuticals, Inc. | Polynucleotides encoding, and method of making, a polypeptide comprising a VHH which binds interleukin-receptor (IL-7R) |
| WO2021092075A1 (en) | 2019-11-05 | 2021-05-14 | Medikine Inc. | IL-2RβγC BINDING COMPOUNDS |
| CN110894237B (zh) * | 2019-12-05 | 2021-08-03 | 山东省分析测试中心 | 抗cd127的抗体、分泌该抗体的细胞株及其制备方法和应用 |
| WO2021158623A1 (en) * | 2020-02-03 | 2021-08-12 | Medikine, Inc. | IL-7Rαγc BINDING COMPOUNDS |
| US20220389104A1 (en) | 2021-05-28 | 2022-12-08 | Ose Immunotherapeutics | Method for Treating CD127-Positive Cancers by Administering an Anti-CD127 Agent |
| CN113501499A (zh) * | 2021-08-11 | 2021-10-15 | 无锡贝塔医药科技有限公司 | 一种高纯无水溴化氘气体的制备方法及其应用 |
| US11999771B2 (en) | 2022-04-07 | 2024-06-04 | Medikine, Inc. | IL-7Rαγc ligand immunoglobulin fusion proteins |
| JP2025518164A (ja) | 2022-05-30 | 2025-06-12 | オセ イムノセラピューティクス | Ｉｌ７ｒモジュレーター活性のバイオマーカー |
| CN115925955B (zh) * | 2022-12-30 | 2025-09-26 | 浙江正熙生物技术有限公司 | 一种抗cd127抗体及其制备方法和应用 |
| EP4455308A1 (en) | 2023-04-24 | 2024-10-30 | Les Laboratoires Servier | Il-7r gene signatures |
| WO2025029859A2 (en) * | 2023-07-31 | 2025-02-06 | Q32 Bio Inc. | Treatment of atopic dermatitis |
| WO2025098341A1 (en) * | 2023-11-10 | 2025-05-15 | Inmagene Biopharmaceuticals (Hangzhou) Co., Ltd. | IL-7Ra TARGETING ANTIBODIES AND USES THEREOF |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201018482A (en) * | 2008-08-08 | 2010-05-16 | Glaxo Wellcome Mfg Pte Ltd | Novel treatment |
| MA34004B1 (fr) * | 2010-01-28 | 2013-02-01 | Glaxo Group Ltd | Protéines de liaison à cd127 |
| AR080291A1 (es) * | 2010-02-24 | 2012-03-28 | Rinat Neuroscience Corp | Anticuerpos antagonistas anti receptor de il-7 y procedimientos |
| EP2583980A1 (en) | 2011-10-19 | 2013-04-24 | Effimune | Antibodies directed against the alpha chain of IL7 receptor - their use for the preparation of drug candidates |
| EP2955196A1 (en) | 2014-06-10 | 2015-12-16 | Effimune | Antibodies directed against CD127 |
| GB201506869D0 (en) * | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method |
-
2017
- 2017-12-07 LT LTEP17835592.1T patent/LT3551664T/lt unknown
- 2017-12-07 ES ES17835592T patent/ES2867900T3/es active Active
- 2017-12-07 AR ARP170103427A patent/AR110326A1/es unknown
- 2017-12-07 UY UY0001037511A patent/UY37511A/es active IP Right Grant
- 2017-12-07 RU RU2019115610A patent/RU2769352C2/ru active
- 2017-12-07 SI SI201730717T patent/SI3551664T1/sl unknown
- 2017-12-07 HU HUE17835592A patent/HUE054206T2/hu unknown
- 2017-12-07 PT PT178355921T patent/PT3551664T/pt unknown
- 2017-12-07 PE PE2019001201A patent/PE20191152A1/es unknown
- 2017-12-07 RS RS20210520A patent/RS61808B1/sr unknown
- 2017-12-07 CA CA3042582A patent/CA3042582C/en active Active
- 2017-12-07 SM SM20210267T patent/SMT202100267T1/it unknown
- 2017-12-07 UA UAA201905605A patent/UA126386C2/uk unknown
- 2017-12-07 WO PCT/EP2017/081911 patent/WO2018104483A1/en not_active Ceased
- 2017-12-07 KR KR1020197019889A patent/KR102306366B1/ko active Active
- 2017-12-07 CN CN201780076086.8A patent/CN110392695B/zh active Active
- 2017-12-07 BR BR112019010595-6A patent/BR112019010595A2/pt active Search and Examination
- 2017-12-07 TW TW106142933A patent/TWI777996B/zh active
- 2017-12-07 AU AU2017373819A patent/AU2017373819B2/en active Active
- 2017-12-07 EA EA201991005A patent/EA201991005A1/ru unknown
- 2017-12-07 MY MYPI2019003245A patent/MY190770A/en unknown
- 2017-12-07 CR CR20190273A patent/CR20190273A/es unknown
- 2017-12-07 DK DK17835592.1T patent/DK3551664T3/da active
- 2017-12-07 PL PL17835592T patent/PL3551664T3/pl unknown
- 2017-12-07 MX MX2019006577A patent/MX2019006577A/es unknown
- 2017-12-07 JP JP2019530803A patent/JP6986559B2/ja active Active
- 2017-12-07 US US16/467,284 patent/US11098128B2/en active Active
- 2017-12-07 NZ NZ753213A patent/NZ753213A/en unknown
- 2017-12-07 EP EP17835592.1A patent/EP3551664B1/en active Active
- 2017-12-07 HR HRP20210697TT patent/HRP20210697T1/hr unknown
- 2017-12-07 MA MA49727A patent/MA49727B1/fr unknown
- 2017-12-07 MD MDE20191173T patent/MD3551664T2/ro unknown
- 2017-12-07 PH PH1/2019/501285A patent/PH12019501285B1/en unknown
-
2019
- 2019-05-02 ZA ZA2019/02743A patent/ZA201902743B/en unknown
- 2019-05-23 IL IL266837A patent/IL266837B/en active IP Right Grant
- 2019-05-30 SA SA519401906A patent/SA519401906B1/ar unknown
- 2019-06-05 CL CL2019001530A patent/CL2019001530A1/es unknown
- 2019-06-05 CO CONC2019/0005909A patent/CO2019005909A2/es unknown
-
2021
- 2021-05-07 CY CY20211100394T patent/CY1124153T1/el unknown
- 2021-06-30 US US17/363,260 patent/US11926671B2/en active Active
-
2024
- 2024-03-09 US US18/600,697 patent/US20240352135A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20190273A (es) | Anticuerpos y polipéptidos dirigidos contra cd127 | |
| CO2020013392A2 (es) | Receptores quiméricos de dll3 y métodos para su uso | |
| MX387587B (es) | Formulaciones subcutáneas de anticuerpos anti-cd38 y sus usos. | |
| EA201791554A1 (ru) | Биспецифичные антитела против cd3 и cd20 | |
| MX384364B (es) | Anticuerpos anti-pd-l1 y sus usos de diagnóstico. | |
| CL2018000728A1 (es) | Anticuerpos anti-cd19 humano humanizados y métodos de utilización | |
| MX2020006715A (es) | Anticuerpos especificos del heterodimero de cd3-delta/epsilon. | |
| MX382129B (es) | Anticuerpos monoclonales contra el epitope de her2 y sus metodos de uso. | |
| MX2023005879A (es) | Anticuerpos biespecificos contra el cd20 humano y el receptor de transferrina humano y metodos de uso. | |
| PE20201419A1 (es) | Anticuerpos anti-hla-g y utilizacion de los mismos | |
| CR20170240A (es) | Anticuerpos anti-interleucina-33 y sus usos | |
| PE20170441A1 (es) | Anticuerpos contra el receptor del factor de necrosis tumoral inducido por glucocorticoides (gitr) y sus usos | |
| CR20160270A (es) | ANTICUERPOS ANTI-TAU (pS422) HUMANIZADOS Y MÉTODOS DE UTILIZACIÓN | |
| CL2016002247A1 (es) | Anticuerpos específicos del receptor del factor 1 de crecimiento similar a la insulina y usos de los mismos | |
| SV2016005352A (es) | Anticuerpos antagonistas del interferon alfa y omega | |
| CL2022001138A1 (es) | Anticuerpos tmem219 y usos terapéuticos de los mismos | |
| CL2019000702A1 (es) | Anticuerpos anti-gm-csf y usos de los mismos. | |
| ECSP22019177A (es) | Proteínas de fusión nkg2d y sus usos | |
| IT201700115761A1 (it) | Bioreattore per la ricellularizzazione e la stimolazione meccanica del diaframma | |
| MX383460B (es) | Derivados peptidicos novedosos y sus usos. | |
| MX2021015922A (es) | Proteínas quiméricas sintéticas estabilizadas y sus usos terapéuticos. | |
| AR119973A1 (es) | Composiciones y métodos de anticuerpos anti-cd39 | |
| AR119984A1 (es) | Proteínas de fusión nkg2d y sus usos | |
| EA201990824A1 (ru) | Антитела, которые связываются с интерлейкином-2, и их применение |